EZALLOR SPRINKLE

PeakSM

rosuvastatin

NDAORALCAPSULE
Approved
Dec 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol.

Clinical Trials (5)

NCT07431866Phase 1Not Yet Recruiting

A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)

Started Apr 2026
39 enrolled
Healthy
NCT07446400Phase 1Not Yet Recruiting

A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together

Started Mar 2026
48 enrolled
Healthy Volunteers
NCT07316608Phase 1Not Yet Recruiting

A Phase I, Open-label, Crossover Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults

Started Mar 2026
44 enrolled
Healthy Participants
NCT07372625Phase 1Not Yet Recruiting

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

Started Jan 2026
NCT07349394Phase 1Active Not Recruiting

Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants

Started Jan 2026
18 enrolled
Cystic Fibrosis

Loss of Exclusivity

LOE Date
Feb 12, 2036
121 months away
Patent Expiry
Feb 12, 2036

Patent Records (1)

Patent #ExpiryTypeUse Code
10413543
Feb 12, 2036
Product